As a leader in our field, The Teewinot Group is making headlines through our cutting-edge approach to cannabinoid based therapies. Learn more about how we plan to further our mission to address unmet medical needs across the globe through some of our latest press releases and company announcements.
Teewinot Life Sciences In the News
March 7, 2017 Teewinot Life Sciences Corporation’s Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids
December 20, 2016 Teewinot Life Sciences CEO, Jeffrey Korentur, quoted in SAT Press Releases, “Nemus Bioscience Announces License of Biosynthetic Technology from Teewinot Life Sciences to Manufacture its Proprietary Cannabinoid Molecules”
December 6, 2016 Teewinot Life Sciences Press Release, “Teewinot Life Sciences’ Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures a New U.S. Patent Covering an Apparatus for Biosynthetic Production of Authentic THCA, CBDA and CBCA Cannabinoids”
November 25, 2016 Teewinot Life Sciences President, Robert Hunt, discusses the cannabinoid market in Scrip Pharma Intelligence | informa, “Cannabinoid Market Snapshot: GW’s Epilepsy Success Bodes Well”
September 12, 2016 Dr. Richard Peet, Executive Vice President and Chief Intellectual Property Counsel at Teewinot Life Sciences Corporation presented a seminar at the Cann10 Conference in Tel Aviv Israel entitled “Biosynthesis of Cannabinoids.” Dr. Peet presented a seminar on Teewinot’s disruptive and patent protected processes for manufacture of pure, pharmaceutical grade cannabinoids, cannabinoid prodrugs and cannabinoid analogs.
March 4, 2016 Teewinot Life Sciences President, Robert Hunt, discussing the how true pharmaceutical based cannabinoid based medicines will be replacing medical cannabis as we know it today (Use password: 420)
Media Relations Contact
Contact: Drew White